Late April and early May are the most flourish times in Denmark. The leaves are sprouting on the trees, the grass is growing quickly, weeds are coming to life and in many places in Denmark the yellow ...

Copenhagen Municipality has completed its first comprehensive mapping of biodiversity across the city. The new report outlines areas where there is potential to preserve, improve, or expand ...

Hours before Trump announced he was pausing all tariffs except those on China, the EU voted to hit back with counter-tariffs ...

Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Greenland appointed its first Arctic ambassador on Friday, pledging to promote sustainable economic development for ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Novo Nordisk A/S has a fifty-two week low of $60.61 and a fifty-two week high of $148.15. The company has a market capitalization of $285.03 billion, a price-to-earnings ratio of 19.31, a P/E/G ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 billion) in Brazil to increase production at its facility in Minas Gerais.

On X, he condemned Frederiksen for her support for Ukraine: “It would be fair take Greenland out of her. She is murderer.” At the helm of Denmark’s economic success is Novo Nordisk ...